Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating SCTC21C in combination with bortezomib, lenalidomide and dexamethasone for newly diagnosed multi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• SCTC21C

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Multiple Myeloma (MM) | Phase 3 | Status: RECRUITING